1-9 of 9
Juan P. Frías
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial

Juliana M. Bue-Valleskey, Christof M. Kazda, Chenchen Ma, Jenny Chien, Qianyi Zhang, Emmanuel Chigutsa, William Landschulz, Axel Haupt, Juan P. Frias
Journal: Diabetes Care
Diabetes Care 2023;46(5):1060–1067
https://doi.org/10.2337/dc22-2396
Published: 21 March 2023
View articletitled, Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial
Open the PDF for Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial in another window
Journal Articles

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

Leigh Perreault, Melanie Davies, Juan P. Frias, Peter Nørkjaer Laursen, Ildiko Lingvay, Sriram Machineni, Anette Varbo, John P.H. Wilding, Signe Olrik Rytter Wallenstein, Carel W. le Roux
Journal: Diabetes Care
Diabetes Care 2022;45(10):2396–2405
https://doi.org/10.2337/dc21-1785
Published: 20 June 2022
View articletitled, Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
Open the PDF for Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program in another window
Journal Articles

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Juan P. Frias, Enzo Bonora, Luis Nevarez Ruiz, Ying G. Li, Zhuoxin Yu, Zvonko Milicevic, Raleigh Malik, M. Angelyn Bethel, David A. Cox
Journal: Diabetes Care
Diabetes Care 2021;44(3):765–773
https://doi.org/10.2337/dc20-1473
Published: 04 January 2021
View articletitled, Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Open the PDF for Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) in another window
Journal Articles

Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

Serge A. Jabbour, Juan P. Frías, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C. David Sjöström, Cristian Guja
Journal: Diabetes Care
Diabetes Care 2020;43(10):2528–2536
https://doi.org/10.2337/dc19-1350
Published: 18 August 2020
View articletitled, Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
Open the PDF for Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial in another window
Journal Articles

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D

Thomas Blevins, Qianyi Zhang, Juan P. Frias, Hideaki Jinnouchi, Annette M. Chang
Journal: Diabetes Care
Diabetes Care 2020;43(12):2991–2998
https://doi.org/10.2337/dc19-2550
Published: 02 July 2020
View articletitled, Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
Open the PDF for Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D in another window
Journal Articles

Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

Jeremy H. Pettus, David D’Alessio, Juan P. Frias, Eric G. Vajda, James D. Pipkin, Julio Rosenstock, Gretchen Williamson, Miriam A. Zangmeister, Lin Zhi, Keith B. Marschke
Journal: Diabetes Care
Diabetes Care 2020;43(1):161–168
https://doi.org/10.2337/dc19-1328
Published: 06 November 2019
View articletitled, Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study
Open the PDF for Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study in another window
Includes: Supplementary data
Journal Articles

More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial

Julio Rosenstock, Alice Cheng, Robert Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M.G. Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P. Frías, Ronan Roussel, Geremia B. Bolli
Journal: Diabetes Care
Diabetes Care 2018;41(10):2147–2154
https://doi.org/10.2337/dc18-0559
Published: 13 August 2018
View articletitled, More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
Open the PDF for More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Serge A. Jabbour, Juan P. Frías, Elise Hardy, Azazuddin Ahmed, Hui Wang, Peter Öhman, Cristian Guja
Journal: Diabetes Care
Diabetes Care 2018;41(10):2136–2146
https://doi.org/10.2337/dc18-0680
Published: 06 August 2018
View articletitled, Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Open the PDF for Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Review of Adverse Events Associated With False Glucose Readings Measured by GDH-PQQ–Based Glucose Test Strips in the Presence of Interfering Sugars

Juan P. Frias, MD, Christine G. Lim, MD, MPH, John M. Ellison, MS, Carol M. Montandon, BS
Journal: Diabetes Care
Diabetes Care 2010;33(4):728–729
https://doi.org/10.2337/dc09-1822
Published: 01 April 2010
View articletitled, Review of Adverse Events Associated With False Glucose Readings Measured by GDH-PQQ–Based Glucose Test Strips in the Presence of Interfering Sugars
Open the PDF for Review of Adverse Events Associated With False Glucose Readings Measured by GDH-PQQ–Based Glucose Test Strips in the Presence of Interfering Sugars in another window
Includes: Supplementary data